


Product Information

Description:	His-tagged Anti-CD20-Anti-CD3 IgM format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CD20-CHO cells (BPS Bioscience #79624-H). The IgM Fc region is pentameric, so there are 5 copies of the anti-CD20 antibodies and J chain has anti-CD3 antibody.
Construct:	Anti-CD20-IgM(1-594(end)-His, 1-241(end)) / Anti-CD3-Jchain(1-415(end))
Concentration:	0.99 mg/ml
Species:	Human
Formulated In:	8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Expression System:	Co-expressed in HEK293
Purification:	Ni-NTA affinity purification of the His-tag protein from HEK293 cells.
Format:	Aqueous buffer solution
Stability:	At least 12 months at -80°C. Avoid freeze/thaw cycles.
Storage:	-80°C
MW:	Anti-CD20 HC: 66 kDa; Anti-CD20 LC: 26 kDa; Anti-CD3 VC: 45 kDa
Purity:	≥90%
Assay Conditions:	<i>Experimental design and assay protocol for measuring anti CD20-anti CD3 functional activity using NFAT-luc reporter Jurkat cell line:</i> Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti CD20 x anti CD3 bispecific antibody in the presence of CD20-CHO cells (BPS Bioscience #79624-H) or CHO cells (ATCC #CCL-61™). 1. Seed CHO and CD20-CHO cells at 30,000 cells/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate. 2. Seed Jurkat cells at 30,000 cells/well. 3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CD20 on CD20-CHO cells. 4. After 16 hours the luciferase activity is measured using ONE-Step™ luciferase assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.
Applications:	This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-CD20-anti-CD3 IgM format bispecific antibody can be used for studying CD20+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as NFAT-luc-Jurkat cells (BPS Bioscience #60621).

Quality Control Data

4-20% SDS-Page Coomassie Staining



Activation of NFAT-Jurkat Reporter by Anti-CD20-Anti-CD3 IgM

